XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Avenzo Therapeutics pays $50M upfront to DualityBio for rights to bispecific antibody-drug conjugate DB-1418. Deal follows ...

Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...

Highlander Health, the clinical trial startup co-founded by former Verily execs Amy Abernethy and Brad Hirsch, is acquiring ...

A 20-year-old biotech working on small molecule treatments for cardiovascular and skeletal muscle diseases has rebranded and ...

WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million ...

Acelyrin has offered a more detailed look at positive Phase 2 data for its thyroid eye disease drug candidate as it tees up ...

The first biopharma venture fund to close in 2025 comes from industry veterans Joe Jimenez and Mark Fishman, two former ...

Oculis' OCS-05 succeeds in Phase 2 trial for acute optic neuritis, showing improved vision and retinal measures. FDA clears ...

Orbis Medicines raises €90M Series A led by NEA for macrocycle drug development, with backing from Eli Lilly, Cormorant Asset ...

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion ...